Berman McAleer LLC Acquires Shares of 4,331 AstraZeneca PLC $AZNCF

Berman McAleer LLC acquired a new stake in AstraZeneca PLC (OTCMKTS:AZNCF) in the first quarter, HoldingsChannel.com reports. The firm acquired 4,331 shares of the company’s stock, valued at approximately $854,000.

Several other large investors have also modified their holdings of AZNCF. Hughes Financial Services LLC purchased a new position in shares of AstraZeneca during the fourth quarter worth approximately $34,000. Fairscale Capital LLC purchased a new stake in AstraZeneca in the 4th quarter valued at $37,000. Bell Investment Advisors Inc purchased a new stake in AstraZeneca in the 1st quarter valued at $39,000. Mascoma Wealth Management LLC purchased a new stake in AstraZeneca in the 4th quarter valued at $46,000. Finally, Aventus Investment Advisors Inc. acquired a new stake in AstraZeneca during the 1st quarter worth $46,000. 40.87% of the stock is owned by institutional investors and hedge funds.

AstraZeneca Price Performance

Shares of AstraZeneca stock opened at $187.10 on Wednesday. AstraZeneca PLC has a 1 year low of $122.26 and a 1 year high of $195.00. The company’s fifty day moving average is $187.10 and its two-hundred day moving average is $186.15.

AstraZeneca Profile

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.